Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Granite Centre
Basel, Switzerlandzoominfo.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Granite Bio has two lead antibody programs. GRT-001 depletes pro-inflammatory monocytes and is in Phase 1a clinical trials in healthy volunteers, with plans for a Phase 1b trial in inflammatory bowel disease patients. GRT-002 targets interleukin‑3 and is expected to enter clinical trials in 2026. Both have shown promising preclinical results regarding efficacy and safety.[1][4]
- Therapeutic areas
- GastroenterologyRare DiseasesImmunology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Partnerships
Versant Ventures’ Ridgeline Discovery EngineUniversity of Regensburg labs of Prof. Matthias Mackinvestors include Novartis Venture Fund, Forbion, Sanofi Ventures
Beyond the preview
Go deeper on Granite Centre.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Granite Centre.